● RetinAI’s software tools combine advanced machine learning algorithms andmedical imaging to enable aggregation, management and analysis of healthdata
● CHF 2.3M pre-Series A investment led by btov Partners’ IndustrialTechnologies Fund
● Contracts signed with large pharmaceutical companies and medical devicemanufacturers
● Company’s first products (Omniviewer, Discovery) already released
● Software enables easy integration of algorithms into clinical and researchworkflows for eye diseases and for monitoring neuropathological disorderslike Alzheimer, Multiple Sclerosis, Parkinson
Bern, 11th Jun 2019 – RetinAI, a Bern based company building software tools to aggregate, manage, and analyze health data, has closed a CHF2.3M pre-SeriesA financing round.btov Partners’ Industrial Technologies Fund has led the round with participation of Swiss-based investornetworkInvestiere and a consortium of selected private investors.
The investment will support RetinAI’ s growth and internationale xpansion. Further, the funds will contribute to growing the team and accelerating certification initiatives.
This brings the company closer to becoming a market reference in the field of healthcare AI.
Today, healthcare is under the pressure of an ever-increasing aging population, growing much faster than the number of health professionals. As a result, waiting time in hospitals increases and, forage-related eye diseases, intensifies the risk of patients losing their eyesight in a malignancy where timing and early diagnosis are crucial.
RetinAI’s “DiscoveryPlatform” makes eye clinics and health institutions more efficient by offering Artificial Intelligence analytics capabilities. The software enables easy integration of algorithms into clinical and research workflows for Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Glaucoma and for monitoring other neuropathological disorders like Alzheimer, MultipleSclerosis, Parkinson,etc.
There by the software solution fosters the transition from reactive to precision and patient-specific medicine.The company integrates its solutions inside the clinic or the pharma server infrastructure and into medical devices, interconnecting the whole clinical pipeline and reducing the time and cost it takes to evaluate patients. This enables doctors to do more in the same amount of time. The last months of the company have been very successful with multiple contracts signed with large pharmaceutical companies and medical device manufacturers and there lease of the company’s first products (Omniviewer, Discovery). Furthermore, the company has received several prestigious grants between December 2018 and January 2019 with more than CHF550 Kinnon-dilutive funding from European (EUROSTARS EU Program) and Swiss (SPHN-Swiss Personalized Healthcare Network) institutions. These grants support the development of new deep Artificial Intelligence technologies and applications.
ChristianSchütz, partner of the Industrial Technologies Fund states: “We are very convinced of the quality and experience of the team in the field of advanced machine learning and medical imaging technologies.
RetinAI’s platform provides tools to structure, analyze and visualize eye examinations while offering a biomarker-based analysis and thus the avoidance of a “blackbox” interpretation of data. Their algorithms allow for clear precision and patient-specific treatment, creating an immense value to Pharma and clinics alike. We believe that RetinAI has the potential to become one of the leading enablers of AI on medical information”.
“One of the biggest issues you find in health institutions is the lack of structure in data originating from medical devices or electronic health records. This situation makes it complicated to identify patterns related to an eyecondition in a reasonable amount of time.
At RetinAI we bring data organisation and analysis to the next level, digesting and funneling information using our algorithms and presenting it to the user in a rich manner.
As a result, clinicians can reach conclusions and take actions faster than ever before. We believe that by combining health data and technology we can transform the field and break the technological barriers that separate patients from the precise treatment they deserve.” says RetinAI’s CEO,Dr. Carlos Ciller.
RetinAI Medical AG (RetinAI), founded in 2016, is a Swiss startup from Bern developing software solutions to make eyecare institutions more efficient using advanced machine learning and computervision. The company builds tools to collect, organise and analyse health data from the eyes, empowering healthcare professionals and patients with unique medical data analysis supported by AI. RetinAI’s international team combines clinical, technical and scientific knowledge to foster the transition from reactive to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy or Glaucoma.
About btov Partners
btov Partners, founded in 2000, is a European venture capital firm founded and funded by serial entrepreneurs and business angels focussing on industrial technologies and digital leaders of the European economy.
The company manages assets of EUR 420 million and examines over 3,000 investment opportunities annually. The btov Industrial Technologies Team has backed companies ranging from component, module and systems hardware companies with embedded software to application and infrastructures of tware suppliers for industrial verticals. Its technology focus lies in robotics & autonomous vehicles, industrial machine learning, Industry 4.0 and Industrial IoT, cyber-physical security, electronics & photonics, additive manufacturing, power conversion and storage, medical and quantum technologies. Past investments include BigRep, Blacklane, Data Artisans, DeepL, Dyemansion, Effect Photonics, Electrochaea, Finanzcheck, ORCAM, Quanta, Raisin, SumUp, Volocopter and XING.
More information at www.btov.vc/industrial-technologies
investiere is the leading European startup investment platform for qualified and institutional investors. Our investment professionals screen thousands of companies and present the best investment opportunities on our digital platform after a rigorous duediligence process.
investiere focuses on European high-tech startups. The investiere community consists of more than 3’500 qualified private investors, family offices and pension funds. Furthermore, numerous Swiss corporates rely on investiere’s VC expert is etoscreen, select and invest in promising startups (clients include Swiss Post, u-blox ,a leading Swiss health insurer, as well as a publishing house).
With CHF 30 million invested in 2018, investiere is Switzerland’s most active startup investor. Zürcher Kantonalbank, the third-largest bank in Switzerland, is a minority shareholder of investiere. To join our international and growing investor community, visit www.investiere.ch
RetinAI Medical AG, All rights reserved © 2016-2019
RetinAI Medical AG
Telefon +49 30 346 55 8400
Mobil +49 152 243 896 83
HOSCHKE & CONSORTEN Public Relations GmbH
Marta Iza de la TorreTelefon +49 40 36 90 50 45 email@example.com
RetinAI Medical AG, All rights reserved © 2016-2019 4